NTLA · ISSUER CIK 1652130
Intellia Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Intellia Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $310K of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$310KInsider selling
−$310KNet open-market
Oct 28, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 202616:06 | Oct 26, 2026 | NTLA | EVP, Chief Medical Officer | A · Grant | — | +199,822 | 199,822 | New | — | ||
| Oct 6, 202616:05 | Oct 2, 2026 | NTLA | VP, Chief Accounting Officer | S · Sell | $12.43 | −1,864 | 65,022 | -3% | −$23K | ||
| Aug 24, 202616:05 | Aug 21, 2026from Aug 20, 2026 | NTLA | President and CEO, Director | S · Sell10b5-1 | $12.65 | −22,675 | 1,147,064 | -2% | −$287K |